Deaths and disability from natalizumab are no longer tolerable: Commentary.
St Vincent's University Hospital and Newman Clinical Research Professor, University College Dublin, Ireland. mhutchin@iol.ie
Michael
M
Hutchinson
D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D006801:Humans; D007049:Iatrogenic Disease; D007155:Immunologic Factors / Q000009:adverse effects*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab
D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab